How to Fight Insurance Denials for IVF, Fertility Preservation, and Reproductive Care

Fertility treatments — IVF cycles, intrauterine insemination (IUI), egg or embryo freezing, preimplantation genetic testing (PGT), donor gametes, and fertility medications — are denied by insurers at rates far higher than many other categories of care. Common reasons include vague claims that treatment is "not medically necessary," incorrect application of infertility definitions that exclude single people or same-sex couples, labeling well-established techniques like PGT-A or oocyte cryopreservation as "experimental," or enforcing arbitrary cycle limits that contradict clinical guidelines. Many patients also face denials for fertility preservation before cancer treatment, despite clear standards of care. This guide explains why these denials happen, which authoritative sources insurers must respect, and how to structure an appeal that cites the exact guidelines, state statutes, and policy language that will carry weight.

---

Why Insurers Deny Fertility Care

Understanding the template language in your denial letter is the first step. Insurers rely on a small set of rationales, most of which can be directly countered with published clinical guidelines and, in many states, explicit statutory mandates.

1. "Treatment is not medically necessary" or "does not meet policy criteria for infertility"

This is the most common denial for IVF and IUI. Insurers often define infertility narrowly — for example, requiring 12 months of unprotected heterosexual intercourse — and reject claims from single individuals, same-sex couples, or patients with diagnosed tubal blockage, azoospermia, or other structural causes who have not "tried" for a full year. The insurer may claim you haven't exhausted lower-cost treatments (like timed intercourse or oral ovulation induction) even when your diagnosis makes those futile.

2. "Experimental" or "investigational" — applied to PGT-A, PGT-M, egg freezing, or other established techniques

Some policies still label preimplantation genetic testing for aneuploidy (PGT-A) or oocyte cryopreservation (egg freezing) as "investigational," even though professional societies removed the experimental designation years ago. This outdated language may appear in older medical policy bulletins that have not been updated to reflect current evidence.

3. "Coverage limit exhausted" — denying an additional IVF cycle after one or two attempts

Many plans impose a hard cap (e.g., "two IVF cycles per lifetime") without regard to the clinical picture. If you're 35 with diminished ovarian reserve and no live birth after one retrieval, the insurer may deny a second cycle purely on a counting rule, ignoring ASRM guidance that multiple cycles are often medically necessary for cumulative success.

4. "Fertility preservation is elective / not covered" — denying egg or sperm freezing before cancer treatment, gender-affirming surgery, or military deployment

This denial is particularly cruel. Insurers sometimes classify oncofertility (fertility preservation before gonadotoxic chemotherapy or radiation) as "elective" or exclude it under blanket fertility-benefit carve-outs, despite unambiguous recommendations from ASRM, ASCO, and NCCN that fertility preservation is standard of care before cancer treatment.

5. "Age exclusion" — denying IVF because you are over 40, 42, or 45

Some policies impose arbitrary age cutoffs. While success rates do decline with age, blanket age-based denials may conflict with medical necessity standards and, in states with mandate laws, may be unlawful if the statute does not permit such exclusions.

---

The Citations Insurers Respect

Appeals succeed when they cite authoritative, named guidelines and — where applicable — the specific statute that governs your plan. Generic references ("studies show…") carry little weight. These are the frameworks that matter.

Clinical Guidelines and Position Statements

• ASRM Practice Committee, "Definitions of infertility and recurrent pregnancy loss" (2020, reaffirmed 2023)

Updated the definition of infertility to include individuals and same-sex couples who require medical intervention to conceive, after an equivalent period of attempted conception with donor sperm or other appropriate means. This directly counters denials that exclude non-heterosexual patients.

• ASRM, "Evidence-based treatments for couples with unexplained infertility: a guideline" (2020)

Establishes IUI with ovarian stimulation and IVF as evidence-based treatments; relevant when insurers demand exhaustion of unproven or lower-yield interventions.

• ASRM, "Fertility evaluation of infertile women: a committee opinion" (2021)

Provides the diagnostic framework; useful when insurers claim you need 12 months of timed intercourse despite a clear anatomic or ovulatory cause.

• ASRM, "Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion" (2019)

Declares fertility preservation (oocyte, embryo, or sperm cryopreservation) before cancer treatment or gender-affirming surgery to be standard of care, not experimental. This is the single most important citation for oncofertility and transgender-care appeals.

• ASRM, "Access to fertility services by transgender and nonbinary persons: an Ethics Committee opinion" (2021)

Affirms that transgender and nonbinary individuals have the same right to fertility services and that denials based on identity or failure to meet heteronormative definitions of infertility are unethical and often unlawful.

• ASRM, "The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion" (2018, updated 2024)

Confirms PGT-A is an established technique, not investigational, and may be indicated for advanced maternal age, recurrent pregnancy loss, or recurrent implantation failure.

• ASRM, "Use of preimplantation genetic testing for monogenic conditions (PGT-M): an Ethics Committee opinion" (2018)

Establishes PGT-M (testing embryos for single-gene disorders) as appropriate when parents are carriers of serious genetic conditions.

• ASRM, "Evaluation and treatment of recurrent pregnancy loss: a committee opinion" (2020)

Supports IVF with PGT when two or more prior losses have occurred and chromosomal causes are suspected.

• ASRM Practice Committee, "Mature oocyte cryopreservation: a guideline" (2013, Fertility and Sterility 99:37–43)

Removed the "experimental" label from oocyte (egg) cryopreservation, making it standard clinical practice. Cite this verbatim when insurers call egg freezing investigational.

• AUA/ASRM Joint Guideline, "Diagnosis and Treatment of Infertility in Men" (2020, amended 2024)

Covers male-factor workup and the role of assisted reproduction when semen parameters are severely abnormal.

• ACOG Committee Opinion 781, "Infertility Workup for the Women's Health Specialist" (2019, reaffirmed)

Reinforces that infertility evaluation — and treatment referral — should begin after six months of attempting conception in women over 35, or immediately if a known cause (e.g., tubal occlusion, anovulation) is present.

• NCCN Clinical Practice Guidelines in Oncology: Adolescent and Young Adult (AYA) Oncology

Recommends discussion of fertility preservation before starting gonadotoxic therapy; cite this for oncofertility denials.

• ASCO, "Fertility Preservation in People With Cancer: ASCO Clinical Practice Guideline Update" (2018, updated 2024)

States that all patients of reproductive age facing gonadotoxic treatment should be offered fertility preservation; insurers cannot call this experimental.

State Mandates (Examples — verify your state and plan type)

State infertility-coverage mandates only apply to fully insured plans (typically individual or small/large-group employer plans regulated under state law). Self-funded ERISA plans are exempt from state mandates, so check your Summary Plan Description to determine your plan type.

• New York: Insurance Law §3221(k)(6) (group), §4303(s) (HMO), §3216(i)(13) (individual)

Requires large-group fully insured plans to cover up to three completed IVF cycles. Cite the specific section that matches your plan type.

• Illinois: 215 ILCS 5/356m

Mandates IVF coverage for large employers (25+ employees); important if your employer is based in Illinois and the plan is state-regulated.

• Massachusetts: M.G.L. c. 175 § 47H, c. 176A § 8K, c. 176B § 4J, c. 176G § 4

One of the strongest mandates, covering diagnosis and treatment of infertility including IVF; applies to most fully insured plans.

• Connecticut, Maryland, New Jersey, Rhode Island, and others

Have varying mandate statutes; if you live or work in one of these states and have a fully insured plan, cite the specific statute in your appeal.

When appealing, quote the statute number and the operative language (e.g., "Under New York Insurance Law §3221(k)(6), large-group policies must provide coverage for up to three completed in vitro fertilization procedures…"). Do not assume the insurer will apply the mandate correctly — many denials result from plan administrators failing to recognize that the statute applies.

---

How to Argue Against Each Major Denial Reason

Fighting "Not Medically Necessary" / "Does Not Meet Infertility Definition"

If you are single, in a same-sex relationship, or require donor gametes:

1. Cite ASRM's 2020/2023 definition verbatim: The committee opinion now defines infertility to include "individuals and couples, including same-sex couples and individuals without partners, who require medical intervention — including, but not limited to, the use of donor gametes or donor embryos or gestational carrier — in order to have a biological child."

2. State explicitly: "My plan's refusal to recognize infertility in the absence of heterosexual intercourse contradicts current medical standards and, where applicable, may violate state anti-discrimination law."

3. Provide documentation of donor-insemination attempts (if applicable) or a letter from your reproductive endocrinologist explaining why IVF or IUI with donor sperm is medically necessary for you to conceive.

If you have a diagnosed cause (tubal factor, anovulation, male-factor azoospermia, endometriosis, etc.):

1. Cite ACOG Opinion 781 and ASRM fertility-evaluation guidelines: When a clear medical cause is present, the 12-month waiting period does not apply; evaluation and treatment should begin immediately.

2. Attach lab results and imaging: HSG showing tubal occlusion, semen analysis showing azoospermia or severe oligospermia, day-3 FSH/AMH documenting diminished ovarian reserve, laparoscopy notes confirming stage III/IV endometriosis.

3. Explain futility: "Because [partner] has obstructive azoospermia confirmed by urologist [name], unassisted conception is biologically impossible. Timed intercourse and ovulation induction are not evidence-based treatments in this scenario. IVF with surgical sperm extraction is the appropriate, medically necessary intervention per ASRM and AUA guidelines."

If the insurer is demanding you "try" cheaper treatments first (e.g., Clomid + timed intercourse when you have bilateral tubal blockage):

1. Cite the specific ASRM guideline that addresses your diagnosis (e.g., tubal factor requires IVF or surgical repair; severe male factor precludes IUI).

2. Use cost-effectiveness language: "Requiring multiple failed IUI cycles when success probability is <5% per the literature wastes time, delays definitive care, reduces my cumulative pregnancy chance due to advancing age, and increases total plan costs."

3. Request an independent medical review (IMR or external review, depending on your state) if the insurer persists.

---

Fighting "Experimental" or "Investigational" Labels

If PGT-A (aneuploidy screening) is denied:

1. Cite ASRM's 2018 (updated 2024) committee opinion on PGT-A, which states it is an established technique and no longer investigational.

2. Provide your clinical indication: advanced maternal age (typically ≥38), recurrent pregnancy loss (≥2), recurrent implantation failure (≥3 failed transfers), or prior aneuploid conception.

3. Quote the insurer's policy bulletin if possible, and contrast it with the ASRM timeline: "Your medical policy [number] was last revised in [year], before ASRM's updated guidance. It does not reflect current standards of care."

If PGT-M (monogenic/single-gene testing) is denied:

1. Cite ASRM's 2018 ethics opinion on PGT-M.

2. Provide genetic counseling documentation: carrier screening showing you and your partner are both carriers for a serious autosomal-recessive condition (e.g., cystic fibrosis, sickle cell, Tay-Sachs), or a known translocation.

3. State the alternative: "Without PGT-M, we face a 25% risk per pregnancy of an affected child and the prospect of pregnancy termination or lifelong severe illness."

If oocyte (egg) cryopreservation is denied as experimental:

1. Cite the 2013 ASRM/Practice Committee guideline that removed the experimental label (Fertility and Sterility 99:37–43).

2. If this is oncofertility (freezing eggs before chemotherapy), also cite ASRM 2019 FP guideline, ASCO 2024 update, and NCCN AYA Oncology guidelines.

3. Include a letter from your oncologist stating the planned regimen is gonadotoxic and that delay for multiple IVF retrievals is not medically feasible.

---

Fighting "Coverage Limit Exhausted"

If you've had one or two IVF cycles without a live birth and the insurer denies further cycles:

1. Cite cumulative live-birth data: ASRM and SART statistics show that for many diagnoses and age groups, multiple cycles are required to achieve a reasonable cumulative success rate. Include your age, AMH, FSH, and prior cycle outcomes (number of mature eggs, fertilization rate, embryo quality, transfer details).

2. Argue medical necessity on an individualized basis: "I am 36 years old with tubal factor infertility and normal ovarian reserve (AMH 3.2 ng/mL). My first cycle yielded five blastocysts; the single euploid embryo transferred resulted in biochemical pregnancy. ASRM guidance supports additional retrievals to achieve a live birth. Denying a second cycle based solely on a plan counting rule ignores my specific prognosis and contradicts evidence-based care."

3. Check your state mandate: Some state laws specify a minimum number of completed cycles (often three in states like NY, MA, IL). If your plan is fully insured and state-regulated, the plan's internal limit may be unlawful.

4. Request external review and cite both clinical guidelines and, if applicable, the state statute.

---

Fighting Fertility-Preservation Denials (Oncofertility, Gender-Affirming Care, Military Deployment)

For cancer patients (oncofertility):

1. Cite all three pillars:

- ASRM 2019: "Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion" — states FP is standard of care, not experimental or elective.

- ASCO 2024 update: Recommends offering FP to all reproductive-age patients before gonadotoxic treatment.

- NCCN AYA Oncology guidelines: Fertility preservation discussion should occur before starting treatment.

2. Attach a letter from your oncologist specifying the planned chemotherapy or radiation regimen, the risk of permanent infertility, and the need for urgent FP.

3. Address timing: "I am scheduled to begin [regimen] on [date]. Oocyte cryopreservation can be completed in approximately two weeks and will not delay my cancer treatment. This is a one-time, narrow window to preserve my fertility."

4. Challenge carve-out language: If the plan excludes "infertility services," argue that FP before iatrogenic infertility is preventive/restorative care, not treatment of pre-existing infertility, and is specifically endorsed by oncology guidelines.

For transgender/nonbinary patients before gender-affirming surgery or hormone therapy:

1. Cite ASRM's 2021 ethics opinion on access to fertility services for transgender and nonbinary persons, which states that these individuals should have equivalent access to FP.

2. Cite ASRM's 2019 FP guideline, which explicitly includes gonadectomy and gender-affirming hormone therapy as indications.

3. If applicable, cite WPATH Standards of Care (World Professional Association for Transgender Health), which recommend discussing fertility preservation before irreversible interventions.

4. Document the irreversibility of the planned treatment and the medical necessity of acting before hormone therapy or surgery.

For military deployment (less commonly covered, but worth raising):

1. Cite Department of Defense policy changes (if applicable to your situation) that now permit service members to access FP before deployment.

2. Frame as preventive care analogous to oncofertility: you are preserving fertility before a situation that may result in injury, exposure, or delayed family-building.

---

Fighting Age-Based Exclusions

1. Check your state statute: Some mandates do not permit insurers to impose age caps; others allow exclusions above a certain age (commonly 45). If your state law is silent, the plan's cap may be challengeable.

2. Provide your individualized prognosis: Even at age 42 or 43, if you have good ovarian reserve (AMH, antral follicle count) and no prior failed cycles, cite success-rate data specific to good-prognosis older patients.

3. Cite ASRM's position that treatment decisions should be individualized, not based on arbitrary age cutoffs.

4. If the plan language is ambiguous (e.g., "coverage available for women under age 45"), argue that "under 45" should be interpreted to include 45, or that the policy is internally inconsistent with the plan's general medical-necessity standard.

---

Practical Steps for Any Appeal

1. Read your Summary Plan Description and any medical policy bulletins the insurer cites. Note the exact policy language and any references.

2. Request all denial letters and internal review records in writing.

3. Gather clinical records: labs (AMH, FSH, estradiol, semen analysis), imaging (HSG, pelvic ultrasound), operative reports (laparoscopy, hysteroscopy), prior cycle reports (if any), genetic carrier screening, biopsy reports (endometriosis, etc.).

4. Obtain a detailed letter of medical necessity from your reproductive endocrinologist (REI), citing the specific ASRM/ACOG/ASCO guidelines listed above and explaining why the requested treatment is evidence-based and appropriate for your diagnosis.

5. Draft your appeal in professional, factual language. Structure:

- Opening paragraph: "I am writing to appeal the denial of [treatment] issued on [date], reference number [X]. This denial is inconsistent with current medical standards of care, published clinical guidelines from the American Society for Reproductive Medicine (ASRM) and other authoritative bodies, and [if applicable] [State] Insurance Law §[statute]."

- Section I: Clinical summary: your diagnosis, relevant test results, prior treatments, why the denied treatment is necessary.

- Section II: Why the denial is wrong: cite each guideline by name and year; quote key passages; explain how they apply to your case.

- Section III [if applicable]: State mandate: quote the statute, explain that your plan is fully insured and subject to the mandate, and state that denial violates state law.

- Conclusion: "I respectfully request that [insurer] overturn this denial, authorize [treatment], and provide written confirmation within [timeframe per your plan's appeal process]."

6. Submit the appeal before the deadline (usually 180 days for internal appeals; external review deadlines vary by state).

7. If the internal appeal is denied, file for external review immediately. External reviewers are independent physicians and are more likely to apply clinical guidelines objectively.

8. Keep meticulous records of all correspondence, submission dates, and phone calls.

---

What We Do

We help patients draft comprehensive, medically grounded appeals by generating letters that cite the authoritative guidelines, state statutes, and policy language insurers must respect. Our tool is built by people who understand both the clinical standards and the bureaucratic tactics insurers use. We don't write vague form letters; we produce clinic-grade appeals tailored to your diagnosis, your plan's specific denial reason, and the legal landscape in your state. If you're facing a denial of IVF, IUI, fertility preservation, PGT, or any reproductive care, we can help you build the strongest possible case — quickly, so you don't lose precious time.

---

Sources

1. American Society for Reproductive Medicine, Practice Committee. "Definitions of infertility and recurrent pregnancy loss: a committee opinion." Fertility and Sterility 2020; 113(3):533–535 (reaffirmed 2023).

2. American Society for Reproductive Medicine, Practice Committee. "Evidence-based treatments for couples with unexplained infertility: a guideline." Fertility and Sterility 2020; 113(2):305–322.

3. American Society for Reproductive Medicine, Practice Committee. "Fertility evaluation of infertile women: a committee opinion." Fertility and Sterility 2021; 116(5):1255–1265.

4. American Society for Reproductive Medicine, Practice Committee. "Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion." Fertility and Sterility 2019; 112(6):1022–1033.

5. American Society for Reproductive Medicine, Ethics Committee. "Access to fertility services by transgender and nonbinary persons: an Ethics Committee opinion." Fertility and Sterility 2021; 115(4):874–878.

6. American Society for Reproductive Medicine, Practice Committee. "The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion." Fertility and Sterility 2018; 109(3):429–436 (updated 2024).

7. American Society for Reproductive Medicine, Ethics Committee. "Use of preimplantation genetic testing for monogenic defects (PGT-M) for adult-onset conditions: an Ethics Committee opinion." Fertility and Sterility 2018; 109(6):989–992.

8. American Society for Reproductive Medicine, Practice Committee. "Evaluation and treatment of recurrent pregnancy loss: a committee opinion." Fertility and Sterility 2020; 114(6):1189–1200 (reaffirmed 2022).

9. American Society for Reproductive Medicine, Practice Committee. "Mature oocyte cryopreservation: a guideline." Fertility and Sterility 2013; 99(1):37–43.

10. American Urological Association and American Society for Reproductive Medicine. "Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline." 2020 (amended 2024). Available at auanet.org.

11. American College of Obstetricians and Gynecologists. "Infertility Workup for the Women's Health Specialist: ACOG Committee Opinion No. 781." Obstetrics & Gynecology 2019; 133(6):e377–e384 (reaffirmed 2021).

12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Adolescent and Young Adult (AYA) Oncology. Version 2.2024. Available at nccn.org.

13. Oktay K, Harvey BE, Partridge AH, et al. "Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update." Journal of Clinical Oncology 2018; 36(19):1994–2001 (updated 2024; summary at asco.org).

14. New York State Insurance Law §3221(k)(6) (group policies), §4303(s) (HMO contracts), §3216(i)(13) (individual policies). Available at nysenate.gov.

15. Illinois Compiled Statutes 215 ILCS 5/356m (Coverage for infertility treatment). Available at ilga.gov.

16. Massachusetts General Laws Chapter 175 §47H, Chapter 176A §8K, Chapter 176B §4J, Chapter 176G §4 (mandated infertility coverage). Available at malegislature.gov.

17. RESOLVE: The National Infertility Association. "Coverage by State" [interactive map of state infertility insurance mandates]. Available at resolve.org.